809 Shares in Stryker Co. (NYSE:SYK) Acquired by Kathmere Capital Management LLC

Kathmere Capital Management LLC bought a new position in Stryker Co. (NYSE:SYK) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 809 shares of the medical technology company’s stock, valued at approximately $291,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of SYK. Edgestream Partners L.P. acquired a new stake in shares of Stryker during the second quarter worth approximately $369,000. Axxcess Wealth Management LLC increased its stake in shares of Stryker by 1.8% in the second quarter. Axxcess Wealth Management LLC now owns 5,167 shares of the medical technology company’s stock worth $1,758,000 after acquiring an additional 93 shares during the last quarter. Argent Trust Co raised its holdings in shares of Stryker by 11.7% during the second quarter. Argent Trust Co now owns 6,918 shares of the medical technology company’s stock worth $2,354,000 after acquiring an additional 722 shares in the last quarter. Bright Financial Advisors Inc. acquired a new stake in Stryker during the second quarter valued at $5,811,000. Finally, Ieq Capital LLC grew its stake in Stryker by 6.0% in the second quarter. Ieq Capital LLC now owns 34,960 shares of the medical technology company’s stock valued at $11,895,000 after purchasing an additional 1,983 shares in the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Stock Performance

NYSE SYK opened at $381.32 on Friday. The company’s fifty day moving average is $375.12 and its two-hundred day moving average is $358.32. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.91 and a quick ratio of 1.22. The firm has a market capitalization of $145.36 billion, a price-to-earnings ratio of 40.87, a P/E/G ratio of 2.51 and a beta of 0.95. Stryker Co. has a 52-week low of $307.23 and a 52-week high of $398.20.

Stryker (NYSE:SYK) last issued its earnings results on Tuesday, October 29th. The medical technology company reported $2.87 EPS for the quarter, topping the consensus estimate of $2.77 by $0.10. The firm had revenue of $5.49 billion during the quarter, compared to analysts’ expectations of $5.37 billion. Stryker had a return on equity of 23.07% and a net margin of 16.34%. Stryker’s quarterly revenue was up 11.9% compared to the same quarter last year. During the same period last year, the business earned $2.46 earnings per share. Equities research analysts forecast that Stryker Co. will post 12.06 EPS for the current year.

Stryker Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Tuesday, December 31st will be paid a $0.84 dividend. The ex-dividend date of this dividend is Tuesday, December 31st. This represents a $3.36 dividend on an annualized basis and a yield of 0.88%. This is a boost from Stryker’s previous quarterly dividend of $0.80. Stryker’s payout ratio is presently 36.01%.

Insider Buying and Selling

In other news, CEO Kevin Lobo sold 57,313 shares of Stryker stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $368.70, for a total value of $21,131,303.10. Following the completion of the transaction, the chief executive officer now owns 100,027 shares in the company, valued at approximately $36,879,954.90. The trade was a 36.43 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 5.90% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the company. Truist Financial raised their price target on Stryker from $380.00 to $409.00 and gave the stock a “hold” rating in a research note on Wednesday, December 18th. Wells Fargo & Company lifted their target price on shares of Stryker from $405.00 to $427.00 and gave the company an “overweight” rating in a research note on Wednesday, December 11th. Evercore ISI increased their price target on shares of Stryker from $380.00 to $384.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 30th. Citigroup lifted their price objective on shares of Stryker from $411.00 to $450.00 and gave the company a “buy” rating in a research note on Wednesday, December 11th. Finally, JPMorgan Chase & Co. upped their price objective on shares of Stryker from $375.00 to $420.00 and gave the stock an “overweight” rating in a report on Wednesday, October 30th. Four investment analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $405.80.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.